Schonfeld Strategic Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-15,906
Closed -$508K 3351
2022
Q2
$508K Sell
15,906
-25,673
-62% -$752K ﹤0.01% 1354
2022
Q1
$1.44M Sell
41,579
-51,961
-56% -$1.55M 0.01% 848
2021
Q4
$2.74M Buy
93,540
+43,067
+85% +$1.33M 0.02% 619
2021
Q3
$1.29M Buy
50,473
+30,973
+159% +$910K 0.01% 867
2021
Q2
$683K Buy
+19,500
New +$761K 0.01% 1054
2021
Q1
Sell
-47,739
Closed -$2.07M 2260
2020
Q4
$2.07M Buy
+47,739
New +$2.35M 0.03% 590
2019
Q3
Sell
-128,700
Closed -$6.77M 1313
2019
Q2
$6.77M Buy
128,700
+55,700
+76% +$3.2M 0.24% 107
2019
Q1
$3.86M Buy
+73,000
New +$3.59M 0.13% 206
2018
Q4
Sell
-11,400
Closed -$433K 1284
2018
Q3
$433K Sell
11,400
-66,100
-85% -$2.93M 0.02% 603
2018
Q2
$3.5M Buy
+77,500
New +$3.53M 0.19% 183
2018
Q1
Sell
-22,350
Closed -$880K 1034
2017
Q4
$880K Sell
22,350
-50,541
-69% -$1.89M 0.07% 330
2017
Q3
$2.26M Buy
+72,891
New +$2.05M 0.21% 141
2016
Q3
Sell
-77,912
Closed -$1.29M 588
2016
Q2
$1.29M Buy
+77,912
New +$1.57M 0.29% 94

Other funds holding GBT

Schonfeld Strategic Advisors's GBT Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 15,906 shares — an estimated $508K sold.

Schonfeld Strategic Advisors first reported a position in GBT in Q2 2016 and held it in 13 quarters. The position peaked at $6.77M in Q2 2019. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,906 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $508K.
  • Schonfeld Strategic Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 13 quarters.
  • Schonfeld Strategic Advisors's Global Blood Therapeutics, Inc. position peaked at $6.77M in Q2 2019.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.